CAR T-Cell Therapy at First Relapse

Living with myeloma means facing decisions at different points in the journey. One of the biggest moments is the first relapse—when the disease returns after initial treatment.

The good news is that treatment options at first relapse are better and more personalized than ever. One of the most promising is CAR T-cell therapy, which geneticallyengineers a person’s own immune cells to target and destroy myeloma cells. For many patients, it offers the possibility of a deep response, time off therapy, and a chance to regain a sense of normalcy.

In this episode, we’ll explore what receiving CAR T-cell therapy after first relapse looks like—who may be a good candidate, how the process works, what thebenefits and risks are, and what the experience is like for clinicians, patients, and caregivers.

Topics of discussion:

(01:49) When does CAR Tbecome something a patient might hear about?

(03:20) Who may be a goodcandidate

(09:15) How the processworks

(13:39) What theexperience is like for clinicians, patients, and caregivers

This episode is supported by AbbVie, Amgen, Bristol Myers Squibb, Genentech, Johnson & Johnson, Legend Biotech, Pfizer, Regeneron, and Sanofi.

To learn more, download the A Guideto CAR T-Cell Therapy in Myeloma Fast Facts in Myeloma sheet here.

To learn more about multiple myeloma, visit www.themmrf.org.

If you want to learn more about the MMRF’s FREE resources for patients and caregivers, visit the MMRF Education Hub.

If you have additional questions, call our MMRF Patient Navigation Center at 1-888-841- 6673.